Insights into the molecular inactivation mechanism of human activated thrombin-activatable fibrinolysis inhibitor

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 5, 2010, Pages 1056-1065

  Sanglas, L ^a   Arolas, J L ^b   Valnickova, Z ^c   Aviles, F X ^a   Enghild, J J ^c   Gomis Ruth F X ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUT DE BIOLOGIA MOLECULAR DE BARCELONA   (Spain)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

Blood coagulation; Metallopeptidase; TAFI; Zymogen activation

Indexed keywords

CARBOXYPEPTIDASE INHIBITOR; PROTEIN INHIBITOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN STABILITY; PROTEIN STRUCTURE; X RAY ANALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; CRYSTALLIZATION; PHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; X RAY CRYSTALLOGRAPHY;

CARBOXYPEPTIDASE B2; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; MODELS, MOLECULAR;

EID: 77953755642     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03740.x     Document Type: Article

References (48)

1. Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. Pathophysiol Haemost Thromb 2003, 33:375-81.
2. Hendriks DF. Carboxypeptidase U. Handbook of Proteolytic Enzymes 2004, 825-8. Barrett AJRawlings NDWoessner JF. In, eds, 2nd edn, London, Elsevier
3. Willemse JL, Hendriks DF. A role for procarboxypepidase U (TAFI) in thrombosis. Front Biosci 2007, 12:1973-87.
4. Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009, 7:4-13.
5. Marx PF. Thrombin-activatable fibrinolysis inhibitor. Curr Med Chem 2004, 11:2335-48.
6. Wang W, Hendriks DF, Scharpe SS. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994, 269:15937-44.
7. Vendrell J, Querol E, Avilés FX. Metallocarboxypeptidases and their protein inhibitors. Structure, function and biomedical properties. Biochim Biophys Acta 2000, 1477:284-98.
8. Willemse JL, Polla M, Hendriks DF. The intrinsic enzymatic activity of plasma procarboxypeptidase U (TAFI) can interfere with plasma carboxypeptidase N assays. Anal Biochem 2006, 356:157-9.
9. Arolas JL, Vendrell J, Aviles FX, Fricker LD. Metallocarboxypeptidases: emerging drug targets in biomedicine. Curr Pharm Des 2007, 13:349-66.
10. Valnickova Z, Thogersen IB, Potempa J, Enghild JJ. Thrombin-activable fibrinolysis inhibitor (TAFI) zymogen is an active carboxypeptidase. J Biol Chem 2007, 282:3066-76.
11. Gomis-Rüth FX. Structure and mechanism of metallocarboxypeptidases. Crit Rev Biochem Mol Biol 2008, 43:319-45.
12. Marx PF, Brondijk TH, Plug T, Romijn RA, Hemrika W, Meijers JC, Huizinga EG. Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation. Blood 2008, 112:2803-9.
13. Anand K, Pallarés I, Valnickova Z, Christensen T, Vendrell J, Wendt KU, Schreuder HA, Enghild JJ, Avilés FX. The crystal structure of thrombin-activable fibrinolysis inhibitor (TAFI) provides the structural basis for its intrinsic activity and the short half-life of TAFIa. J Biol Chem 2008, 283:29416-23.
14. Mao SS, Cooper CM, Wood T, Shafer JA, Gardell SJ. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B. Modulation by glycosaminoglycans. J Biol Chem 1999, 274:35046-52.
15. Boffa MB, Wang W, Bajzar L, Nesheim ME. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J Biol Chem 1998, 273:2127-35.
16. Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002, 277:1021-30.
17. Valnickova Z, Christensen T, Skottrup P, Thogersen IB, Hojrup P, Enghild JJ. Post-translational modifications of human thrombin-activatable fibrinolysis inhibitor (TAFI): evidence for a large shift in the isoelectric point and reduced solubility upon activation. Biochemistry 2006, 45:1525-35.
18. Valnickova Z, Thaysen-Andersen M, Hojrup P, Christensen T, Sanggaard KW, Kristensen T, Enghild JJ. Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI). BMC Biochem 2009, 10:13.
19. Tams JW, Welinder KG. Mild chemical deglycosylation of horseradish peroxidase yields a fully active, homogeneous enzyme. Anal Biochem 1995, 228:48-55.
20. Marx PF, Verkleij CJ, Seron MV, Meijers JC. Recent developments in thrombin-activatable fibrinolysis inhibitor research. Mini Rev Med Chem 2009, 9:1165-73.
21. Marx PF, Plug T, Havik SR, Morgelin M, Meijers JC. The activation peptide of thrombin-activatable fibrinolysis inhibitor: a role in activity and stability of the enzyme? J Thromb Haemost 2009, 7:445-52.
22. Boffa MB, Bell R, Stevens WK, Nesheim ME. Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 2000, 275:12868-78.
23. Boffa MB, Nesheim ME, Koschinsky ML. Thrombin activable fibrinolysis inhibitor (TAFI): molecular genetics of an emerging potential risk factor for thrombotic disorders. Curr Drug Targets Cardiovasc Haematol Disord 2001, 1:59-74.
24. Otlewski J, Jelen F, Zakrzewska M, Oleksy A. The many faces of protease-protein inhibitor interaction. EMBO J 2005, 24:1303-10.
25. Barbosa Pereira PJ, Segura-Martin S, Oliva B, Ferrer-Orta C, Avilés FX, Coll M, Gomis-Rüth FX, Vendrell J. Human procarboxypeptidase B: three-dimensional structure and implications for thrombin-activatable fibrinolysis inhibitor (TAFI). J Mol Biol 2002, 321:537-47.
26. Sanglas L, Aviles FX, Huber R, Gomis-Ruth FX, Arolas JL. Mammalian metallopeptidase inhibition at the defense barrier of Ascaris parasite. Proc Natl Acad Sci USA 2009, 106:1743-7.
27. Sanglas L, Valnickova Z, Arolas JL, Pallarés I, Guevara T, Solà M, Kristensen T, Enghild JJ, Avilés FX, Gomis-Rüth FX. Structure of activated thrombin-activatable fibrinolysis inhibitor, a molecular link between coagulation and fibrinolysis. Mol Cell 2008, 31:598-606.
28. Kabsch W. International Tables for Crystallography Volume F: Crystallography of Biological Macromolecules 2001, 730-4. Rossmann MGArnold E. In, eds, 1st edn, Dordrecht, Kluwer Academic Publishers (for The International Union of Crystallography)
29. Evans P. Scaling and assessment of data quality. Acta Crystallogr D 2006, 62:72-82.
30. Navaza J. AMoRe: an automated package for molecular replacement. Acta Crystallogr A 1994, 50:157-63.
31. Carranza C, Inisan A-G, Mouthuy-Knoops E, Cambillau C, Roussel A. Turbo-Frodo. AFMB Activity Report 1996-1999. Marseille, CNRS-UPR, 9039, 1999: 89-90
32. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D 1997, 53:240-55.
33. Coll M, Guasch A, Aviles FX, Huber R. Three-dimensional structure of porcine procarboxypeptidase B: a structural basis of its inactivity. EMBO J 1991, 10:1-9.
34. Evans SV. SETOR: hardware lighted three-dimensional solid model representations of macromolecules. J Mol Graphics 1993, 11:134-8.
35. Schatteman KA, Goossens FJ, Scharpe SS, Hendriks DF. Proteolytic activation of purified human procarboxypeptidase U. Clin Chim Acta 2000, 292:25-40.
36. Komori Y, Chiang KT, Fukuto JM. The effect of nonionic detergents on the activity and/or stability of rat brain nitric oxide synthase. Arch Biochem Biophys 1993, 307:311-15.
37. Reverter D, Vendrell J, Canals F, Horstmann J, Avilés FX, Fritz H, Sommerhoff CP. A carboxypeptidase inhibitor from the medical leech Hirudo medicinalis. Isolation, sequence analysis, cDNA cloning, recombinant expression, and characterization. J Biol Chem 1998, 273:32927-33.
38. Arolas JL, Lorenzo J, Rovira A, Castella J, Aviles FX, Sommerhoff CP. A carboxypeptidase inhibitor from the tick Rhipicephalus bursa: isolation, cDNA cloning, recombinant expression, and characterization. J Biol Chem 2005, 280:3441-8.
39. Walker JB, Hughes B, James I, Haddock P, Kluft C, Bajzar L. Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro. J Biol Chem 2003, 278:8913-21.
40. Reverter D, Fernandez-Catalan C, Baumgartner R, Pfander R, Huber R, Bode W, Vendrell J, Holak TA, Aviles FX. Structure of a novel leech carboxypeptidase inhibitor determined free in solution and in complex with human carboxypeptidase A2. Nat Struct Biol 2000, 7:322-8.
41. Arolas JL, Popowicz GM, Lorenzo J, Sommerhoff CP, Huber R, Avilés FX, Holak TA. The three-dimensional structures of tick carboxypeptidase inhibitor in complex with A/B carboxypeptidases reveal a novel double-headed binding mode. J Mol Biol 2005, 350:489-98.
42. Knecht W, Willemse J, Stenhamre H, Andersson M, Berntsson P, Furebring C, Harrysson A, Hager AC, Wissing BM, Hendriks D, Cronet P. Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demonstrates the importance of CPU stability over proCPU concentration in down-regulating fibrinolysis. FEBS J 2006, 273:778-92.
43. Marx PF, Hackeng TM, Dawson PE, Griffin JH, Meijers JC, Bouma BN. Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage. J Biol Chem 2000, 275:12410-15.
44. Hillmayer K, Macovei A, Pauwels D, Compernolle G, Declerck PJ, Gils A. Characterization of rat thrombin-activatable fibrinolysis inhibitor (TAFI) - a comparative study assessing the biological equivalence of rat, murine and human TAFI. J Thromb Haemost 2006, 4:2470-7.
45. Rodgers GM. Role of antithrombin concentrate in treatment of hereditary antithrombin deficiency. An update. Thromb Haemost 2009, 101:806-12.
46. Zappacosta F, Pessi A, Bianchi E, Venturini S, Sollazzo M, Tramontano A, Marino G, Pucci P. Probing the tertiary structure of proteins by limited proteolysis and mass spectrometry: the case of Minibody. Prot Sci 1996, 5:802-13.
47. Valnickova Z, Thogersen IB, Christensen S, Chu CT, Pizzo SV, Enghild JJ. Activated human plasma carboxypeptidase B is retained in the blood by binding to α2-macroglobulin and pregnancy zone protein. J Biol Chem 1996, 271:12937-43.
48. Zirlik A. TAFI: a promising drug target? Thromb Haemost 2004, 91:420-2.